CTOs on the Move

Intact Vascular

www.intactvascular.com

 
Founded in 2011, Intact Vascular located in Wayne, PA is a privately held medical device company that develops minimally invasive peripheral vascular products. The Tack Endovascular System™ is designed to optimize peripheral balloon angioplasty results in the treatment of peripheral artery disease. This technology will offer physicians a new treatment option for treating peripheral artery disease. Intact Vascular is committed to developing safe, efficacious and easy to use products for patients with vascular disease and for the physicians who treat them.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Intact Vascular raised $38M on 05/14/2015
Intact Vascular raised $46M on 01/03/2017
Intact Vascular raised $20M on 04/16/2018
Intact Vascular raised $25M on 05/30/2019

Similar Companies

Celladon

Celladon is a privately held biotechnology company founded with the goal of developing molecular therapies for cardiovascular diseases. Breakthroughs in the basic understanding of the cardiovascular networks combined with powerful new technologies have provided the foundation for new, rational, and technologically sophisticated approaches to cardiovascular treatments. Our first product candidate is designed to target the key enzyme deficiency in advanced heart failure which regulates calcium cycling and contractility in heart muscle cells.

ChemNavigator

ChemNavigator is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

resTORbio

resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.

Eyetech Pharmaceuticals

Eyetech Pharmaceuticals, Inc. is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lumen Bioscience

Lumen Bioscience develops oral antibody therapeutics.